Therapy But Better – Lifestyle
Author:
Nasus Pharma, Ltd.
Nasus Pharma to Participate in Upcoming Investor Conferences
May 1, 2026
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
March 27, 2026
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
March 27, 2026
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
March 25, 2026
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
March 16, 2026